A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01616303 |
Recruitment Status
:
Active, not recruiting
First Posted
: June 11, 2012
Last Update Posted
: April 17, 2018
|
Sponsor:
Quest PharmaTech Inc.
Information provided by (Responsible Party):
Quest PharmaTech Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | December 2018 |
Estimated Study Completion Date : | December 2019 |